Print
Email
Gene therapy has been a subject of intense research and development for decades. It has the potential to revolutionize the way we treat various diseases by altering the genetic material of a patient's cells. However, one major hurdle in the effective delivery of gene therapy has been the inability to target specific cells in the body. However, researchers, biotech companies and scientists are in continuous search for the affordable solution.
Traditional gene therapy methods involve the use of viral vectors to deliver the therapeutic gene to the target cells. However, these vectors can cause adverse reactions and immune responses in some patients. Additionally, viral vectors can only target a limited number of cells in the body. This means that the therapeutic gene may not reach all the cells that need it, reducing the effectiveness of the treatment.
Exosomes technology offers several advantages over traditional gene therapy methods. Exosomes are naturally occurring in the body, which reduces the risk of adverse reactions and immune responses. Additionally, exosomes can target a wide range of cells in the body, including those that are difficult to reach with viral vectors. This makes technology more efficient and effective than traditional gene therapy methods. The exosomes are loaded with therapeutic genes and injected into the patient's bloodstream. The exosomes can then travel to the target cells and deliver the therapeutic genes. Once inside the target cells, the therapeutic genes can replace or repair the faulty genes that are causing the disease.
Why employ an exosome when lipid nanoparticles (LNP) are cheap, simple to manufacture, and straightforward to monitor their quality? The answer is that repeated delivery of LNPs might not be as safe. There are recognised side effects of LNP toxicity, and under a repeated administration treatment paradigm, the immune system may eventually reject the LNPs. Together, these factors strongly support the need for efficient and safe methods of delivering bioactive chemicals into cells. Furthermore, compared to creating an exosome, engineering an LNP might not be a more economical option. Exosomes are a strong contender to close this hole in the creation of innovative biotherapies.
Exosomes generated from mesenchymal stem cells are currently being tested in clinical studies for the treatment of acute ischemic stroke (NCT 0 338 4433), Alzheimer's disease (NCT 0 438 8982), and macula hole repair (NCT0347759).
Exosome-based cancer vaccines, which have undergone many clinical studies, and exosome-based vaccinations for newly developing infectious illnesses, such as Ebola and influenza virus, among others, are further promising prospective clinical uses for exosomes.
However, in order to improve the characterisation of exosomal drugs as carriers and obtain more dependable therapeutic and diagnostic outcomes, BioIntel360 suggests that deeper research are required that include cutting-edge technologies like machine learning, scRNA-seq, and high-throughput screening. Furthermore, more clinical trials are required to demonstrate the efficacy of exosomes as potential everyday treatment agents and biomarker tools for tumours and other cancers.
